Status:
TERMINATED
Study of MT-5111 in HER2-positive Solid Tumors
Lead Sponsor:
Molecular Templates, Inc.
Conditions:
HER2-positive Solid Cancers
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This will be a Phase 1b, first in human, open-label, dose escalation and expansion study of MT-5111 (a recombinant fusion protein) given as monotherapy in subjects with HER2-positive solid tumors
Detailed Description
This study will be conducted in two parts: Part A (Dose Escalation): The purpose of Part A is to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D). Part A will include any...
Eligibility Criteria
Inclusion
- Histologically confirmed, unresectable, locally advanced or metastatic solid cancers:
- Part A (Dose-Escalation): All HER2-positive solid cancers are eligible
- Part B (Dose-Expansion): Any type of HER2-positive solid cancer, including breast cancer, and gastric or gastroesophageal adenocarcinomas (GEA).
- HER2-positive in the latest tumor sample tested for HER2 (testing to be done on a metastatic lesion in cases of metastatic cancers).
- Relapsed or refractory to or intolerant of existing therapy(ies)
- At least 1 measurable or evaluable lesion according to RECIST 1.1 (Subjects with evaluable disease only may be included in the dose escalation phase)
- ECOG performance score of ≤ 1
- Adequate Bone marrow function as determined by:
- Absolute neutrophil count (ANC) ≥ 1,000/mm3
- Platelet count ≥ 75,000 mm³ and
- Hemoglobin ≥ 8.0 g/dL
- Red blood cell transfusion within 2 weeks of study treatment start is allowed if hemoglobin levels remain stable
- Kidney function:
- Creatinine clearance (CLcr) ≥ 50 mL/min either measured or estimated using the Cockcroft-Gault formula
- Cardiac Function:
- Left ventricular ejection fraction (LVEF) ≥ 55% on the echocardiogram (ECHO) assessment (preferred), or multigated acquisition (MUGA) scan, and QTcF ≤ 480 ms for women and QTcF ≤ 450 ms for men \[average from three QTcF values on the triplicate 12-lead electrocardiogram (ECG)\] at baseline
- Hepatic function:
- Total bilirubin ≤ 1.5 x ULN, or ≤ 3 x ULN for subjects with Gilbert's Syndrome and
- AST ≤ 3 x ULN (or ≤ 5 x ULN if liver metastasis) and ALT ≤ 3 x ULN (or ≤ 5 x ULN if liver metastasis)
Exclusion
- History or current evidence of another tumor that is histologically distinct from the tumor under study
- Current evidence of new or growing CNS metastases during screening
- Subjects with known CNS metastases will be eligible if they meet protocol specified criteria
- Evidence of CTCAE Grade \>1 toxicity before the start of treatment, except for hair loss and those Grade 2 toxicities listed as permitted in other eligibility criteria
- History or evidence of significant cardiovascular disease
- Current evidence of active, uncontrolled hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV) (evidenced by detectable viral load by PCR) or acquired immunodeficiency syndrome (AIDS) related illness
- Current evidence of ≥ grade 2 underlying pulmonary disease
- Certain exclusionary prior treatments
Key Trial Info
Start Date :
November 12 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 27 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04029922
Start Date
November 12 2019
End Date
April 27 2023
Last Update
June 18 2023
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic (Arizona)
Phoenix, Arizona, United States, 85054
2
St. Joseph Heritage Healthcare
Fullerton, California, United States, 92835
3
Cancer and Blood Specialty Clinic
Los Alamitos, California, United States, 90720
4
Cedars-Sinai Medical Center
Santa Monica, California, United States, 90048